{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:05:22Z","timestamp":1781003122036,"version":"3.54.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>With the advent of anti-\u03b2-amyloid therapies, clinical distinction between A\u03b2\u2009+\u2009and A\u03b2\u2212 in cognitive impairment is becoming increasingly important for stratifying referral and better utilization of biomarker assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cognitive profile, rate of decline, neuropsychiatric inventory questionnaire (NPI-Q), and imaging characteristics were collected from 52 subjects with possible\/probable AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Participants with A\u03b2+ status had lower baseline MMSE scores (24.50 vs. 26.85, <jats:italic>p<\/jats:italic>\u2009=\u20090.009) and higher total NPI-Q scores (2.73 vs. 1.18, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). NPI-Q score was found to be the only independent predictor for \u03b2-amyloid positivity (<jats:italic>p<\/jats:italic>\u2009=\u20090.008). A simple scoring system, namely Clinical \u03b2-Amyloid Positivity Prediction Score (CAPS), was developed by using the following parameters: NPI-Q, rapidity of cognitive decline, and white matter microangiopathy. Data from 48 participants were included in the analysis of accuracy of CAPS. CAP Score of 3 or 4 successfully classified A\u03b2\u2009+\u2009individuals in 86.7% cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Clinical \u03b2-Amyloid Positivity Prediction Score is a simple clinical tool for use in primary care and memory clinic settings to predict \u03b2-amyloid positivity in individuals with clinical Alzheimer Syndrome can potentially facilitate referral for Anti A\u03b2 therapies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1422681","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:40:20Z","timestamp":1723614020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["CAPS: a simple clinical tool for \u03b2-amyloid positivity prediction in clinical Alzheimer syndrome"],"prefix":"10.3389","volume":"15","author":[{"given":"Durjoy","family":"Lahiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Seixas-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas Paul","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmad","family":"Al-Shamaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Chertkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.24125","article-title":"Mild to moderate Alzheimer dementia with insufficient neuropathological changes","volume":"75","author":"Serrano-Pozo","year":"2014","journal-title":"Ann Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaneurol.2015.1721","article-title":"Characterizing apolipoprotein E \u03b54 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal \u03b2-amyloid peptide plaques","volume":"72","author":"Monsell","year":"2015","journal-title":"JAMA Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/BF00293396","article-title":"Hippocampal sclerosis: a common pathological feature of dementia in very old (\u226580 years of age) humans","volume":"88","author":"Dickson","year":"1994","journal-title":"Acta Neuropathol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/brain\/awr053","article-title":"Hippocampal sclerosis in advanced age: clinical and pathological features","volume":"134","author":"Nelson","year":"2011","journal-title":"Brain"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00401-013-1154-1","article-title":"Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease","volume":"126","author":"Nelson","year":"2013","journal-title":"Acta Neuropathol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/WAD.0b013e31820f8f50","article-title":"Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically","volume":"25","author":"Pao","year":"2011","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcz046","article-title":"Is tau in the absence of amyloid on the Alzheimer\u2019s continuum?: a study of discordant PET positivity","volume":"2","author":"Weigand","year":"2020","journal-title":"Brain Commun"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/JAD-160077","article-title":"Hippocampal sclerosis of aging, a common Alzheimer\u2019s disease \u2018mimic\u2019: risk genotypes are associated with brain atrophy outside the temporal lobe","volume":"52","author":"Nho","year":"2016","journal-title":"J Alzheimer's Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","article-title":"Primary age-related tauopathy (PART): a common pathology associated with human aging","volume":"128","author":"Crary","year":"2014","journal-title":"Acta Neuropathol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","article-title":"Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI","volume":"86","author":"Landau","year":"2016","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1093\/brain\/aww159","article-title":"Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer\u2019s disease","volume":"139","author":"Ch\u00e9telat","year":"2016","journal-title":"Brain"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/brain\/awz162","article-title":"White matter hyperintensities: relationship to amyloid and tau burden","volume":"142","author":"Graff-Radford","year":"2019","journal-title":"Brain"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/jgs.18124","article-title":"Conversion between the Montreal cognitive assessment and the mini-mental status examination","volume":"71","author":"Fasnacht","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"The Gerontologist"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","article-title":"Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory","volume":"12","author":"Kaufer","year":"2000","journal-title":"J Nat Products"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/archneur.1975.00490510088009","article-title":"Cerebral blood flow in dementia","volume":"32","author":"Hachinski","year":"1975","journal-title":"Arch Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/jnnp.69.5.630","article-title":"Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study","volume":"69","author":"Wahlund","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"Am J Roentgenol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e075037","DOI":"10.1002\/alz.075037","article-title":"A comparative study of amyloid positive and negative individuals with \u201cAlzheimer syndrome\u201d","volume":"19","author":"Lahiri","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/medicina57050503","article-title":"Foundational statistical principles in medical research: sensitivity, specificity, positive predictive value, and negative predictive value","volume":"57","author":"Monaghan","year":"2021","journal-title":"Medicina"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-021-00949-7","article-title":"Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer\u2019s disease","volume":"14","author":"Creese","year":"2022","journal-title":"Alzheimer's Res Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/JAD-190025","article-title":"Neuropsychiatric symptoms and risk of progression to Alzheimer\u2019s disease among mild cognitive impairment subjects","volume":"70","author":"Dietlin","year":"2019","journal-title":"J Alzheimer's Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neurobiolaging.2019.10.008","article-title":"Apathy and anxiety are early markers of Alzheimer\u2019s disease","volume":"85","author":"Johansson","year":"2020","journal-title":"Neurobiol Aging"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000090674","article-title":"Neuropathologic correlates of apathy in Alzheimer\u2019s disease","volume":"21","author":"Marshall","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/08919887211016068","article-title":"Plasma \u03b2-amyloid in mild behavioural impairment\u2014neuropsychiatric symptoms on the Alzheimer\u2019s continuum","volume":"35","author":"Miao","year":"2022","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/380168a0","article-title":"\u03b2-Amyloid-mediated vasoactivity and vascular endothelial damage","volume":"380","author":"Thomas","year":"1996","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fnagi.2015.00200","article-title":"A\u03b2 clearance, \u201chub\u201d of multiple deficiencies leading to Alzheimer disease","volume":"7","author":"Gallina","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(03)00305-3","article-title":"Vascular cognitive impairment","volume":"2","author":"O\u2019Brien","year":"2003","journal-title":"Lancet Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e0204313","DOI":"10.1371\/journal.pone.0204313","article-title":"Association between white matter lesions and cerebral A\u03b2 burden. Ginsberg SD, editor","volume":"13","author":"Yi","year":"2018","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jalz.2012.04.006","article-title":"Cerebral white matter disease is associated with Alzheimer pathology in a prospective cohort","volume":"8","author":"Moghekar","year":"2012","journal-title":"Alzheimer\u2019s Dement"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00401-017-1738-2","article-title":"Parietal white matter lesions in Alzheimer\u2019s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease","volume":"134","author":"McAleese","year":"2017","journal-title":"Acta Neuropathol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4082\/kjfm.18.0144","article-title":"Medial temporal atrophy alone is insufficient to predict underlying Alzheimer\u2019s disease pathology","volume":"41","author":"Jeong","year":"2020","journal-title":"Kor J Fam Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamaneurol.2016.1017","article-title":"Association of cerebral microbleeds with cognitive decline and dementia","volume":"73","author":"Akoudad","year":"2016","journal-title":"JAMA Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/brain\/awq321","article-title":"Brain microbleeds and Alzheimer\u2019s disease: innocent observation or key player?","volume":"134","author":"Cordonnier","year":"2011","journal-title":"Brain"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of Gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1212\/01.wnl.0000256697.20968.d7","article-title":"Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease","volume":"68","author":"Devanand","year":"2007","journal-title":"Neurology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neurobiolaging.2012.03.010","article-title":"Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers","volume":"34","author":"Lehmann","year":"2013","journal-title":"Neurobiol Aging"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the global CEO initiative on Alzheimer\u2019s disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e082874","DOI":"10.1002\/alz.082874","article-title":"Quantitative amyloid-PET in real-world practice: lessons from the imaging dementia\u2014evidence for amyloid scanning (IDEAS) study","volume":"19","author":"La Joie","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S2666-7568(23)00019-3","article-title":"The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia","volume":"4","author":"Nichols","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2174\/156720512801322663","article-title":"Overview and findings from the rush memory and aging project","volume":"9","author":"Bennett","year":"2012","journal-title":"Cardiology"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","article-title":"Biological subtypes of Alzheimer disease: A systematic review and meta-analysis","volume":"94","author":"Ferreira","year":"2020","journal-title":"Neurology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e5960","DOI":"10.1002\/gps.5960","article-title":"Relationships between neuropsychiatric symptoms and cognitive profiles in Alzheimer\u2019s disease and related syndromes","volume":"38","author":"Seixas-Lima","year":"2023","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1422681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:40:23Z","timestamp":1723614023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1422681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":52,"alternative-id":["10.3389\/fneur.2024.1422681"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1422681","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"article-number":"1422681"}}